Skip to main content

Table 2 Reasons to include the patient in the system

From: Feasibility of a genotyping system for the diagnosis of alpha1 antitrypsin deficiency: a multinational cross-sectional analysis

 

Argentina (n = 2491)

Brazil (n = 2620)

Chile (n = 3352)

Colombia (n = 2057)

LATAM (n = 10,520)

Spain (n = 18,272)

Turkey (n = 2035)

Total (n = 30,827)

COPD

1234 (49.5)

1909 (72.9)

1189 (35.5)

1936 (94.1)

6268 (59.6)

7025 (38.4)

1936 (95.1)

15,230 (49.4)

Poorly controlled asthma

682 (27.4)

183 (7.0)

325 (9.7)

61 (3.0)

1251 (11.9)

2095 (11.5)

35 (1.7)

3381 (11.0)

Bronchiectasis

127 (5.1)

267 (10.2)

155 (4.6)

76 (3.7)

625 (5.9)

777 (4.3)

33 (1.6)

1435 (4.7)

Serum AAT concentration level below the limit of normality

0 (0.0)

34 (1.3)

2 (0.1)

0 (0.0)

36 (0.3)

321 (1.8)

0 (0.0)

357 (1.2)

Blood relatives of individuals with AATD

2 (0.1)

176 (6.7)

11 (0.3)

0 (0.0)

189 (1.8)

548 (3.0)

28 (1.4)

765 (2.5)

Spouses of individuals with AATD

0 (0.0)

8 (0.3)

1 (0.0)

0 (0.0)

9 (0.1)

21 (0.1)

0 (0.0)

30 (0.1)

Hepatopathy of unknown cause

6 (0.2)

79 (3.0)

6 (0.2)

0 (0.0)

91 (0.9)

200 (1.1)

3 (0.1)

294 (1.0)

Dyspnea and chronic cough in many family members

272 (10.9)

39 (1.5)

93 (2.8)

0 (0.0)

404 (3.8)

368 (2.0)

7 (0.3)

779 (2.5)

Decreased or lack of peak alpha-1 protein on proteinogram

3 (0.1)

17 (0.6)

3 (0.1)

1 (0.0)

24 (0.2)

551 (3.0)

2 (0.1)

577 (1.9)

Panniculitis or multiorgan vasculitis of unknown cause

8 (0.3)

14 (0.5)

2 (0.1)

0 (0.0)

24 (0.2)

16 (0.1)

1 (0.0)

41 (0.1)

SARS-CoV-2 infection

4 (0.2)

28 (1.1)

190 (5.7)

0 (0.0)

222 (2.1)

1262 (6.9)

0 (0.0)

1484 (4.8)

None of the above

191 (7.7)

85 (3.2)

1453 (43.3)

27 (1.3)

1756 (16.7)

5937 (32.5)

8 (0.4)

7701 (25.0)

  1. Data expressed as absolute (relative) frequencies. Percentages referred to the total number per country